HighTower Advisors’s Barinthus Biotherapeutics BRNS Stock Holding History

HighTower Advisors’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.7K	Hold	37,450	–	–	﹤0.01%	3762
2026 Q1	$21.3K	Hold	37,450	–	–	﹤0.01%	3756
2025 Q4	$26.2K	Hold	37,450	–	–	﹤0.01%	3603
2025 Q3	$46.8K	Hold	37,450	–	–	﹤0.01%	3617
2025 Q2	$34.8K	Hold	37,450	–	–	﹤0.01%	3581
2025 Q1	$36.4K	Buy	+37,450	New	+$38.5K	﹤0.01%	3478

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

GLR Partners Columbia, Maryland $215M AUM

HighTower Advisors's BRNS Position: Q2 2026 in Review

HighTower Advisors held its Barinthus Biotherapeutics (BRNS) position steady in Q2 2026 at 37,450 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

HighTower Advisors first reported a position in BRNS in Q1 2025 and has held it in 6 quarters since. The position peaked at $46.8K in Q3 2025. 3 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

HighTower Advisors held 37,450 shares of Barinthus Biotherapeutics worth $24.7K as of Q2 2026.
HighTower Advisors left its Barinthus Biotherapeutics share count unchanged in Q2 2026.
Barinthus Biotherapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3762 holding.
HighTower Advisors first reported a position in Barinthus Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
HighTower Advisors's Barinthus Biotherapeutics position peaked at $46.8K in Q3 2025.
3 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.